Omalizumab for treating severe persistent allergic asthma

  • Technology appraisal guidance
  • TA278
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology is considered for review by the Guidance Executive in March 2016. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
April 2013